Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

John R Corboy

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-NEUR General Operations
Phone303/724-2196
    Other Positions
    TitleAssoc Chair
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-NEUR General Operations

    TitleProfessor
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-NEUR General Operations


    Collapse Research 
    Collapse research activities and funding
    R03MH056832     (CORBOY, JOHN R)Jul 1, 1997 - Jun 30, 2000
    NIH
    GENE EXPRESSION STUDIES USING BRAIN DERIVED HIV1 LTRS
    Role: Principal Investigator
    K08NS001673     (CORBOY, JOHN R)Jul 1, 1993 - Jun 30, 1998
    NIH
    MODELS OF AIDS DEMENTIA COMPLEX
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 Jan 01; 81(1):87. PMID: 37983039.
      View in: PubMed
    2. Borko TL, Baxter R, Cabrera-Martinez B, Thiruppathi E, Sabalza M, Venkataraman I, Selva S, Rester C, Sillau S, Pastula DM, Bennett JL, Alvarez E, Gross R, Shah A, Kammeyer R, Corboy JR, Kedl RM, Hsieh EWY, Piquet AL. SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients. J Neuroimmunol. 2023 10 15; 383:578192. PMID: 37666038.
      View in: PubMed
    3. Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W, Waubant EL, Yamout B, Cohen JA. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023 08; 22(8):750-768. PMID: 37479377.
      View in: PubMed
    4. Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023 07; 22(7):568-577. PMID: 37353277.
      View in: PubMed
    5. Shafit-Zagardo B, Sidoli S, Goldman JE, DuBois JC, Corboy JR, Strittmatter SM, Guzik H, Edema U, Arackal AG, Botbol YM, Merheb E, Nagra RM, Graff S. TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury. Cells. 2023 06 27; 12(13). PMID: 37443768.
      View in: PubMed
    6. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz?lez J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588. PMID: 36811392.
      View in: PubMed
    7. Shah AA, Wolf AB, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR. Challenging Cases in Neuroimmunology. Semin Neurol. 2022 12; 42(6):695-707. PMID: 36690027.
      View in: PubMed
    8. Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021; 12:799138. PMID: 35145470.
      View in: PubMed
    9. Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069359. PMID: 35024160.
      View in: PubMed
    10. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170. PMID: 34364034.
      View in: PubMed
    11. Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 07 01; 78(7):787-788. PMID: 33871561.
      View in: PubMed
    12. Piquet AL, Corboy JR, Vollmer TL. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211019567. PMID: 34104219.
      View in: PubMed
    13. Corboy JR, Jones EC, Barbano RL, Anderson DC. 2019-2020: A Message From the Editors to Our Reviewers. Neurol Clin Pract. 2021 Feb; 11(1):e1-e5. PMID: 33968478.
      View in: PubMed
    14. Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020; 11:1045. PMID: 33071934.
      View in: PubMed
    15. Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2020 Aug 24. PMID: 32852530.
      View in: PubMed
    16. Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476. PMID: 32767538.
      View in: PubMed
    17. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487. PMID: 32767531.
      View in: PubMed
    18. Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. PMID: 31644992.
      View in: PubMed
    19. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402. PMID: 31542710.
      View in: PubMed
    20. Mowry EM, Corboy JR. Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. Lancet Neurol. 2019 11; 18(11):983-985. PMID: 31492653.
      View in: PubMed
    21. Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735. PMID: 31162313.
      View in: PubMed
    22. Corboy JR, Powers LB, Anderson DC, Barbano RL. Message from the Editors to our Reviewers. Neurol Clin Pract. 2019 Apr; 9(2):90-92. PMID: 31041121.
      View in: PubMed
    23. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):845-854. PMID: 30794930.
      View in: PubMed
    24. Corboy JR. Giving voice to patients. Neurol Clin Pract. 2019 Feb; 9(1):1. PMID: 30858995.
      View in: PubMed
    25. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732. PMID: 30635477.
      View in: PubMed
    26. Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262. PMID: 30847358.
      View in: PubMed
    27. Corboy JR. Tools to address health care delivery challenges and improve patient outcomes. Neurol Clin Pract. 2018 Dec; 8(6):463. PMID: 30588371.
      View in: PubMed
    28. Gould JR, Reineberg AE, Cleland BT, Knoblauch KE, Clinton GK, Banich MT, Corboy JR, Enoka RM. Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis. Front Physiol. 2018; 9:1404. PMID: 30386250.
      View in: PubMed
    29. Corboy JR. Strength in numbers. Neurol Clin Pract. 2018 Oct; 8(5):363. PMID: 30564476.
      View in: PubMed
    30. Corboy JR. Real-world practice. Neurol Clin Pract. 2018 Aug; 8(4):275. PMID: 30140570.
      View in: PubMed
    31. Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. PMID: 30140580.
      View in: PubMed
    32. Nuwer MR, Corboy JR. Curbside consults join the telemedicine era. Neurol Clin Pract. 2018 Jun; 8(3):177-178. PMID: 30105154.
      View in: PubMed
    33. Corboy JR. Providing patient-centered care in the digital era. Neurol Clin Pract. 2018 Jun; 8(3):171. PMID: 30105147.
      View in: PubMed
    34. Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018 06 12; 90(24):1106-1112. PMID: 29685920.
      View in: PubMed
    35. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93. PMID: 29801915.
      View in: PubMed
    36. Corboy JR. Partners in enhancing functional ability and well-being. Neurol Clin Pract. 2018 Apr; 8(2):83. PMID: 29708226.
      View in: PubMed
    37. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018; 13(2):e0192109. PMID: 29394264.
      View in: PubMed
    38. Corboy JR, Powers LB, Anderson DC, Barbano RL. Message from the Editors to our Reviewers. Neurol Clin Pract. 2018 Feb; 8(1):2-3. PMID: 29517054.
      View in: PubMed
    39. Corboy JR. The physician as captain of the patient-centered ship. Neurol Clin Pract. 2018 Feb; 8(1):1. PMID: 29517064.
      View in: PubMed
    40. Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology. 2018 02 27; 90(9):e797-e807. PMID: 29386274.
      View in: PubMed
    41. Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep; 3(3):2055217317725102. PMID: 28839949.
      View in: PubMed
    42. Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017 Sep; 13(9):567-572. PMID: 28799551.
      View in: PubMed
    43. Corboy JR. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary. Mult Scler. 2017 08; 23(9):1192-1193. PMID: 28673113.
      View in: PubMed
    44. Hardy TA, Corboy JR, Weinshenker BG. Bal? concentric sclerosis evolving from apparent tumefactive demyelination. Neurology. 2017 05 30; 88(22):2150-2152. PMID: 28468846.
      View in: PubMed
    45. Kister I, Corboy J. Author response: Reducing costs while enhancing quality of care in MS. Neurology. 2017 03 21; 88(12):1212. PMID: 28320926.
      View in: PubMed
    46. Kister I, Corboy JR. Reducing costs while enhancing quality of care in MS. Neurology. 2016 Oct 11; 87(15):1617-1622. PMID: 27590294.
      View in: PubMed
    47. Klein E, Solomon AJ, Corboy J, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. Mult Scler Relat Disord. 2016 Jul; 8:4-8. PMID: 27456867.
      View in: PubMed
    48. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol. 2016 Mar; 18 Suppl 2:ii13-ii20. PMID: 26989128.
      View in: PubMed
    49. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21. PMID: 26888980.
      View in: PubMed
    50. Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15(1):35-46. PMID: 26621682.
      View in: PubMed
    51. McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8b. PMID: 25726030.
      View in: PubMed
    52. Solomon AJ, Klein EP, Corboy JR, Bernat JL. Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. Mult Scler. 2015 Oct; 21(12):1593-9. PMID: 25716879.
      View in: PubMed
    53. Larsen DP, Butler AC, Aung WY, Corboy JR, Friedman DI, Sperling MR. The effects of test-enhanced learning on long-term retention in AAN annual meeting courses. Neurology. 2015 Feb 17; 84(7):748-54. PMID: 25609761.
      View in: PubMed
    54. Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014 Nov; 3(6):696-704. PMID: 25891548.
      View in: PubMed
    55. Corboy JR. The relationship between physicians and Pharma: Playing the devil's advocate. Neurol Clin Pract. 2014 Apr; 4(2):161-163. PMID: 24790801.
      View in: PubMed
    56. Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 May 15; 270(1-2):75-85. PMID: 24690203.
      View in: PubMed
    57. Corboy JR. Manipulating the nervous system: The brave new world. Neurol Clin Pract. 2013 Dec; 3(6):455-456. PMID: 30107012.
      View in: PubMed
    58. Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 2014 Mar; 3(2):227-36. PMID: 25878010.
      View in: PubMed
    59. Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct; 19(9):995-1008. PMID: 24059259.
      View in: PubMed
    60. Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10; 81(11):1022-3. PMID: 24019388.
      View in: PubMed
    61. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85. PMID: 23725360.
      View in: PubMed
    62. Corboy JR. The revolution of practice. Neurol Clin Pract. 2013 Apr; 3(2):87. PMID: 29473609.
      View in: PubMed
    63. Corboy JR. Annual checkup. Neurol Clin Pract. 2012 Dec; 2(4):263-264. PMID: 30123676.
      View in: PubMed
    64. Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May; 38(1):37-42. PMID: 23200463.
      View in: PubMed
    65. Corboy JR. Practice across borders. Neurol Clin Pract. 2012 Sep; 2(3):169-170. PMID: 29443291.
      View in: PubMed
    66. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 Jul; 71(7):604-17. PMID: 22710964.
      View in: PubMed
    67. Corboy JR. Broadening our vision. Neurol Clin Pract. 2012 Jun; 2(2):89-90. PMID: 29443296.
      View in: PubMed
    68. Schowinsky J, Corboy J, Vollmer T, Kleinschmidt-DeMasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012 May; 123(5):751-2. PMID: 22407011.
      View in: PubMed
    69. Corboy JR. Call for submissions! Neurol Clin Pract. 2012 Mar; 2(1):1-2. PMID: 29443282.
      View in: PubMed
    70. Corboy JR. Breaking clinical ground. Neurol Clin Pract. 2011 Dec; 1(1):1. PMID: 29443314.
      View in: PubMed
    71. Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther. 2011 Aug; 91(8):1166-83. PMID: 21680771.
      View in: PubMed
    72. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98. PMID: 21651327.
      View in: PubMed
    73. Freeman WD, Nolte CM, Matthews BR, Coleman M, Corboy JR. Results of the American Academy of Neurology resident survey. Neurology. 2011 Mar 29; 76(13):e61-7. PMID: 21444895.
      View in: PubMed
    74. Miravalle A, Corboy JR. Therapeutic options in multiple sclerosis: five new things. Neurology. 2010 Nov 02; 75(18 Suppl 1):S22-7. PMID: 21041767.
      View in: PubMed
    75. Corboy JR, Miravalle AA. Emerging therapies for treatment of multiple sclerosis. J Inflamm Res. 2010; 3:53-9. PMID: 22096357.
      View in: PubMed
    76. Haug A, Mahalingam R, Cohrs RJ, Schmid DS, Corboy JR, Gilden D. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature. J Neurol Sci. 2010 May 15; 292(1-2):85-8. PMID: 20170926.
      View in: PubMed
    77. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, St?ve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009 Apr; 256(4):568-76. PMID: 19444532.
      View in: PubMed
    78. Butler MA, Corboy JR, Filley CM. How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis. Neuropsychol Rev. 2009 Sep; 19(3):399-410. PMID: 19373561.
      View in: PubMed
    79. Kleinschmidt-Demasters BK, Cummings TJ, Hulette CM, Morgenlander JC, Corboy JR. Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder. J Neuropathol Exp Neurol. 2009 Apr; 68(4):432-9. PMID: 19287308.
      View in: PubMed
    80. Schuh LA, Adair JC, Drogan O, Kissela BM, Morgenlander JC, Corboy JR. Education research: neurology residency training in the new millennium. Neurology. 2009 Jan 27; 72(4):e15-20. PMID: 19171823.
      View in: PubMed
    81. Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52. PMID: 18952560.
      View in: PubMed
    82. Corboy JR, Elkind MS. Maintenance of certification: ready or not, here it comes. Neurology. 2008 Aug 19; 71(8):544-5. PMID: 18711107.
      View in: PubMed
    83. Owens GP, Winges KM, Ritchie AM, Edwards S, Burgoon MP, Lehnhoff L, Nielsen K, Corboy J, Gilden DH, Bennett JL. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol. 2007 Nov 01; 179(9):6343-51. PMID: 17947712.
      View in: PubMed
    84. Gill DJ, Freeman WD, Thoresen P, Corboy JR. Residency training the neurology resident case log: a national survey of neurology residents. Neurology. 2007 May 22; 68(21):E32-3. PMID: 17515532.
      View in: PubMed
    85. Brousseau KM, Arciniegas DB, Carmosino MJ, Corboy JR. The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic. Mult Scler. 2007 Jul; 13(6):749-53. PMID: 17613603.
      View in: PubMed
    86. Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM. MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically? J Clin Exp Neuropsychol. 2007 Feb; 29(2):142-54. PMID: 17365249.
      View in: PubMed
    87. Corboy JR, Gault J, Kleinschmidt-DeMasters BK. An adult case of leukoencephalopathy with intracranial calcifications and cysts. Neurology. 2006 Nov 28; 67(10):1890-2. PMID: 17130435.
      View in: PubMed
    88. Hudson LA, Bernard TJ, Tseng BS, Miller BR, Corboy JR. Neuromyelitis optica immunoglobulin G in a child. Pediatr Neurol. 2006 Nov; 35(5):370-2. PMID: 17074612.
      View in: PubMed
    89. Simon JH, Zhang S, Laidlaw DH, Miller DE, Brown M, Corboy J, Bennett J. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. J Magn Reson Imaging. 2006 Nov; 24(5):983-8. PMID: 17024655.
      View in: PubMed
    90. Adair JC, Rudnicki SA, Boudreau E, Weiner WJ, Coyle PK, Corboy JR. Survey of training programs' means for promoting neurology and attracting trainees. Neurology. 2006 Sep 26; 67(6):936-9. PMID: 17000957.
      View in: PubMed
    91. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul; 63(7):964-8. PMID: 16831965.
      View in: PubMed
    92. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr; 63(4):614-9. PMID: 16606781.
      View in: PubMed
    93. Frohman EM, St?ve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct; 62(10):1519-30. PMID: 16216934.
      View in: PubMed
    94. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol. 2005 Sep; 62(9):1345-56. PMID: 16157741.
      View in: PubMed
    95. Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol. 2005 Apr; 62(4):585-90. PMID: 15824257.
      View in: PubMed
    96. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol. 2005 Mar; 36(3):282-90. PMID: 15791573.
      View in: PubMed
    97. Coombs BD, Best A, Brown MS, Miller DE, Corboy J, Baier M, Simon JH. Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler. 2004 Aug; 10(4):392-7. PMID: 15327035.
      View in: PubMed
    98. Ritchie AM, Gilden DH, Williamson RA, Burgoon MP, Yu X, Helm K, Corboy JR, Owens GP. Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol. 2004 Jul 01; 173(1):649-56. PMID: 15210828.
      View in: PubMed
    99. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 May 15; 363(9421):1607-8. PMID: 15145635.
      View in: PubMed
    100. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003 Sep 23; 61(6):848-50. PMID: 14504338.
      View in: PubMed
    101. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 09; 61(5):602-11. PMID: 12963748.
      View in: PubMed
    102. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol. 2003 Sep 01; 171(5):2725-33. PMID: 12928426.
      View in: PubMed
    103. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003 Oct 01; 102(7):2364-72. PMID: 12763935.
      View in: PubMed
    104. Corboy JR, Goodin DS, Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2003 Jan; 5(1):35-54. PMID: 12521562.
      View in: PubMed
    105. Corboy JR, Boudreau E, Morgenlander JC, Rudnicki S, Coyle PK. Neurology residency training at the millennium. Neurology. 2002 May 28; 58(10):1454-60. PMID: 12034779.
      View in: PubMed
    106. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, Carlson S, Corboy J, Parren PW, Sanna PP, Gilden DH, Burton DR. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1793-8. PMID: 11172030.
      View in: PubMed
    107. Singh M, Corboy JR, Stears JC, Kleinschmidt-DeMasters BK. Diffuse leptomeningeal gliomatosis associated with multifocal CNS infarcts. Surg Neurol. 1998 Oct; 50(4):356-62; discussion 362. PMID: 9817460.
      View in: PubMed
    108. Corboy JR, Garl PJ, Kleinschmidt-DeMasters BK. Human herpesvirus 8 DNA in CNS lymphomas from patients with and without AIDS. Neurology. 1998 Feb; 50(2):335-40. PMID: 9484350.
      View in: PubMed
    109. Corboy JR, Garl PJ. HIV-1 LTR DNA sequence variation in brain-derived isolates. J Neurovirol. 1997 Oct; 3(5):331-41. PMID: 9372454.
      View in: PubMed
    110. Corboy JR, Buzy JM, Zink MC, Clements JE. Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. Science. 1992 Dec 11; 258(5089):1804-8. PMID: 1465618.
      View in: PubMed
    111. Corboy JR, Galetta SL. Familial cavernous angiomas manifesting with an acute chiasmal syndrome. Am J Ophthalmol. 1989 Sep 15; 108(3):245-50. PMID: 2774032.
      View in: PubMed
    Corboy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (369) concept(s)
    _
    Co-Authors Expand Description
    See all (34) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)